 | • レポートコード：MRC23Q35752 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、86ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の急性骨髄性白血病（AML）バイオマーカー検査市場について調査・分析し、世界の急性骨髄性白血病（AML）バイオマーカー検査市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（遺伝性急性骨髄性白血病（AML）バイオマーカー、エピジェネティック急性骨髄性白血病（AML）バイオマーカー、プロテオーム性急性骨髄性白血病（AML）バイオマーカー）、用途別セグメント分析（病院、がん診断センター、研究所、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Abbott Laboratories、Novartis AG、Thermo Fisher Scientific、Cancer Genetics Inc.、Sysmex Corporation、Epigenomics AG、BioMerieux SA、Skyline DX B.V.などが含まれています。世界の急性骨髄性白血病（AML）バイオマーカー検査市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、急性骨髄性白血病（AML）バイオマーカー検査市場規模を推定する際に考慮しました。本レポートは、急性骨髄性白血病（AML）バイオマーカー検査の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、急性骨髄性白血病（AML）バイオマーカー検査に関するビジネス上の意思決定に役立てることを目的としています。 ・急性骨髄性白血病（AML）バイオマーカー検査市場の概要 - 急性骨髄性白血病（AML）バイオマーカー検査のタイプ別セグメント - 世界の急性骨髄性白血病（AML）バイオマーカー検査市場規模：タイプ別分析（遺伝性急性骨髄性白血病（AML）バイオマーカー、エピジェネティック急性骨髄性白血病（AML）バイオマーカー、プロテオーム性急性骨髄性白血病（AML）バイオマーカー） - 急性骨髄性白血病（AML）バイオマーカー検査の用途別セグメント - 世界の急性骨髄性白血病（AML）バイオマーカー検査市場規模：用途別分析（病院、がん診断センター、研究所、その他） - 世界の急性骨髄性白血病（AML）バイオマーカー検査市場規模予測（2018年-2029年） ・急性骨髄性白血病（AML）バイオマーカー検査市場の成長トレンド - 急性骨髄性白血病（AML）バイオマーカー検査の地域別市場規模（2018年-2029年） - 急性骨髄性白血病（AML）バイオマーカー検査市場ダイナミクス - 急性骨髄性白血病（AML）バイオマーカー検査の業界動向 - 急性骨髄性白血病（AML）バイオマーカー検査市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：遺伝性急性骨髄性白血病（AML）バイオマーカー、エピジェネティック急性骨髄性白血病（AML）バイオマーカー、プロテオーム性急性骨髄性白血病（AML）バイオマーカー - 世界の急性骨髄性白血病（AML）バイオマーカー検査のタイプ別市場規模（2018年-2023年） - 世界の急性骨髄性白血病（AML）バイオマーカー検査のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、がん診断センター、研究所、その他 - 世界の急性骨髄性白血病（AML）バイオマーカー検査の用途別市場規模（2018年-2023年） - 世界の急性骨髄性白血病（AML）バイオマーカー検査の用途別市場規模（2024年-2029年） ・急性骨髄性白血病（AML）バイオマーカー検査の地域別市場規模 - 北米の急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年） - アメリカの急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年） - ヨーロッパの急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年） - アジア太平洋の急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年） - 中国の急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年） - 日本の急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年） - 韓国の急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年） - インドの急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年） - オーストラリアの急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年） - 中南米の急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年） - 中東・アフリカの急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Abbott Laboratories、Novartis AG、Thermo Fisher Scientific、Cancer Genetics Inc.、Sysmex Corporation、Epigenomics AG、BioMerieux SA、Skyline DX B.V. ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Acute Myeloid Leukemia (AML) Biomarker Testing market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Acute Myeloid Leukemia (AML) Biomarker Testing is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Acute Myeloid Leukemia (AML) Biomarker Testing is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Acute Myeloid Leukemia (AML) Biomarker Testing in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Acute Myeloid Leukemia (AML) Biomarker Testing include Abbott Laboratories, Novartis AG, Thermo Fisher Scientific, Cancer Genetics Inc., Sysmex Corporation, Epigenomics AG, BioMerieux SA and Skyline DX B.V., etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Acute Myeloid Leukemia (AML) Biomarker Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Myeloid Leukemia (AML) Biomarker Testing.
The Acute Myeloid Leukemia (AML) Biomarker Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Acute Myeloid Leukemia (AML) Biomarker Testing market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Myeloid Leukemia (AML) Biomarker Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Abbott Laboratories
Novartis AG
Thermo Fisher Scientific
Cancer Genetics Inc.
Sysmex Corporation
Epigenomics AG
BioMerieux SA
Skyline DX B.V.
Segment by Type
Genetic Acute Myeloid Leukemia (AML) Biomarker
Epigenetic Acute Myeloid Leukemia (AML) Biomarker
Proteomic Acute Myeloid Leukemia (AML) Biomarker
Segment by Application
Hospitals
Cancer diagnostic Centers
Research Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Myeloid Leukemia (AML) Biomarker Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Genetic Acute Myeloid Leukemia (AML) Biomarker
1.2.3 Epigenetic Acute Myeloid Leukemia (AML) Biomarker
1.2.4 Proteomic Acute Myeloid Leukemia (AML) Biomarker
1.3 Market by Application
1.3.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Cancer diagnostic Centers
1.3.4 Research Institutes
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Perspective (2018-2029)
2.2 Acute Myeloid Leukemia (AML) Biomarker Testing Growth Trends by Region
2.2.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Acute Myeloid Leukemia (AML) Biomarker Testing Historic Market Size by Region (2018-2023)
2.2.3 Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Region (2024-2029)
2.3 Acute Myeloid Leukemia (AML) Biomarker Testing Market Dynamics
2.3.1 Acute Myeloid Leukemia (AML) Biomarker Testing Industry Trends
2.3.2 Acute Myeloid Leukemia (AML) Biomarker Testing Market Drivers
2.3.3 Acute Myeloid Leukemia (AML) Biomarker Testing Market Challenges
2.3.4 Acute Myeloid Leukemia (AML) Biomarker Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Players by Revenue
3.1.1 Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Players by Revenue (2018-2023)
3.1.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share by Players (2018-2023)
3.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Acute Myeloid Leukemia (AML) Biomarker Testing Revenue
3.4 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Concentration Ratio
3.4.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in 2022
3.5 Acute Myeloid Leukemia (AML) Biomarker Testing Key Players Head office and Area Served
3.6 Key Players Acute Myeloid Leukemia (AML) Biomarker Testing Product Solution and Service
3.7 Date of Enter into Acute Myeloid Leukemia (AML) Biomarker Testing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Acute Myeloid Leukemia (AML) Biomarker Testing Breakdown Data by Type
4.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Historic Market Size by Type (2018-2023)
4.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Type (2024-2029)
5 Acute Myeloid Leukemia (AML) Biomarker Testing Breakdown Data by Application
5.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Historic Market Size by Application (2018-2023)
5.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2018-2029)
6.2 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2018-2023)
6.4 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2018-2029)
7.2 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2018-2023)
7.4 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2018-2029)
8.2 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region (2018-2023)
8.4 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2018-2029)
9.2 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2018-2023)
9.4 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2018-2029)
10.2 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2018-2023)
10.4 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.1.4 Abbott Laboratories Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
11.1.5 Abbott Laboratories Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Detail
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.2.4 Novartis AG Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
11.2.5 Novartis AG Recent Development
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Detail
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.3.4 Thermo Fisher Scientific Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
11.3.5 Thermo Fisher Scientific Recent Development
11.4 Cancer Genetics Inc.
11.4.1 Cancer Genetics Inc. Company Detail
11.4.2 Cancer Genetics Inc. Business Overview
11.4.3 Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.4.4 Cancer Genetics Inc. Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
11.4.5 Cancer Genetics Inc. Recent Development
11.5 Sysmex Corporation
11.5.1 Sysmex Corporation Company Detail
11.5.2 Sysmex Corporation Business Overview
11.5.3 Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.5.4 Sysmex Corporation Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
11.5.5 Sysmex Corporation Recent Development
11.6 Epigenomics AG
11.6.1 Epigenomics AG Company Detail
11.6.2 Epigenomics AG Business Overview
11.6.3 Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.6.4 Epigenomics AG Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
11.6.5 Epigenomics AG Recent Development
11.7 BioMerieux SA
11.7.1 BioMerieux SA Company Detail
11.7.2 BioMerieux SA Business Overview
11.7.3 BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.7.4 BioMerieux SA Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
11.7.5 BioMerieux SA Recent Development
11.8 Skyline DX B.V.
11.8.1 Skyline DX B.V. Company Detail
11.8.2 Skyline DX B.V. Business Overview
11.8.3 Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.8.4 Skyline DX B.V. Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
11.8.5 Skyline DX B.V. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details